RAD51 and PALB2 in precision oncology: Clinical implications for HRD associated breast and ovarian cancers (Review)
International Journal of Oncology · 03.07.2025 · 67 (2) · 1-16
DOI: 10.3892/ijo.2025.5771 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Oncology, online erschienen am 03.07.2025. Verfasst von Mohd Adnan Kausar und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, College of Medicine, University of Ha'il, Hail 2440, Saudi Arabia. Hauptthemen laut MEDLINE: Fanconi Anemia Complementation Group N Protein, Ovarian Neoplasms, Breast Neoplasms, Rad51 Recombinase. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 175 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Maintaining genomic stability is essential for reducing the risk of carcinogenesis. Homologous recombination (HR) is a high‑fidelity DNA repair mechanism that addresses double‑strand breaks and interstrand crosslinks. The present review examined two key components of HR: RAD51, the eukaryotic recombinase and PALB2, a scaffolding protein. Their structural and functional roles are explored in the context of breast and ovarian cancer. RAD51 facilitates homology search and strand invasion, while PALB2 links BRCA1 and BRCA2, stabilizing RAD51 filaments. Mutations in these genes compromise HR, increasing susceptibility to various cancers and impacting treatment efficacy by impairing DNA repair. The present review discussed the clinical implications of RAD51 and PALB2 mutations, focusing on risk stratification, PARP inhibitor efficacy and emerging therapies. Additionally, it highlighted the potential of RAD51 and PALB2 as biomarkers and therapeutic targets, contributing to advances in personalized cancer management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, College of Medicine, University of Ha'il, Hail 2440, Saudi Arabia.
- Department of Internal Medicine, College of Medicine, University of Ha'il, Hail 2440, Saudi Arabia.
- Department of Pharmacology, College of Medicine, University of Ha'il, Hail 2440, Saudi Arabia.
- Department of Pathology, College of Medicine, University of Ha'il, Hail 2440, Saudi Arabia.
- Department of Medical Laboratory Sciences, College of Applied Medical Sciences, University of Bisha, Bisha 67714, Saudi Arabia.
- School of Biosciences, Apeejay Stya University, Gurugram, Haryana 122103, India.
Zitieren
APA
Kausar, M. A., Alshammari, K. F., Alenazi, F., Anwar, S., Khalifa, A. M., Ginawi, T., Asiri, A., Najm, M. Z., Rabbani, S. A., El-Tanani, M., & Gantayat, S. (2025). RAD51 and PALB2 in precision oncology: Clinical implications for HRD associated breast and ovarian cancers (Review). International Journal of Oncology, 67(2), 1-16. https://doi.org/10.3892/ijo.2025.5771
Vancouver
Kausar MA, Alshammari KF, Alenazi F, Anwar S, Khalifa AM, Ginawi T, et al. RAD51 and PALB2 in precision oncology: Clinical implications for HRD associated breast and ovarian cancers (Review). International Journal of Oncology. 2025;67(2):1-16. doi:10.3892/ijo.2025.5771
BibTeX
@article{Kausar2025,
author = {Kausar, Mohd Adnan and Alshammari, Khalid Farhan and Alenazi, Fahaad and Anwar, Sadaf and Khalifa, Amany Mohammed and Ginawi, Tarig and Asiri, Abdulaziz and Najm, Mohammad Zeeshan and Rabbani, Syed Arman and El-Tanani, Mohamed and Gantayat, Saumyatika},
title = {RAD51 and PALB2 in precision oncology: Clinical implications for HRD associated breast and ovarian cancers (Review)},
journal = {International Journal of Oncology},
year = {2025},
volume = {67},
number = {2},
pages = {1--16},
doi = {10.3892/ijo.2025.5771}
}
EUVIMED